Research detection kit PC202302019

for MYD88 geneclinicalcell

The L265P mutation of the MYD88 gene leads to the substitution of proline at position 265 of the Toll-IL-1 receptor domain (TIR) of the MYD88 protein. It can trigger the activation of NF-kB signal mediated by interleukin-1 receptor-related kinase, promote cell proliferation, and is considered to be involved in the pathogenesis of certain malignant tumors. Studies have found that the MYD88 L265P mutation exists in more than 90% of LPL/WM (lymphoplasmacytic lymphoma/Wahrenheit macroglobulinemia) patients, while it is rarely detected in other B-cell tumors with similar clinical pathology. Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft versus host disease (cGVHD). Patients with MYD88 gene mutation have a good response to ibrutinib and are safe in pre-treatment. DETECTION SIGNIFICANCE 1. Auxiliary diagnosis of lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia. 2. Select patients for the treatment of LPL/WM with Ibrutinib based on the presence of MYD88 L265P mutation. FEATURES & ADVANTAGES 1. Accuracy and Reliability: Use pre-load PCR tube to effectively avoid cross-contamination. 2. Ease of Use: The process is standardized and the experimental procedure is simple. 3. Great Versatility：Validated on the most common qPCR machines with stable results. DETECTION PROCESS 1、Nucleic Acid Extraction 3、Amplification 4、Data Analysis